Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix PDT vs Placebo in Primary Nodular Basal Cell Carcinoma
NCT00472043Phase 3Completed
- Sponsor
- Galderma
- Start
- Oct 2000
- Primary completion
- Sep 2002
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in basal cell carcinoma (BCC) comparing Metvix PDT with Placebo PDT (2 arms). Primary endpoint: Percentage of Participants With Histologically Confirmed Complete Response (CR) at 6 months. Started Oct 2000; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT00472043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00472043.